US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

LeonaBio, Inc. - Common Stock (NQ:LONA)

4.820 +0.440 (+10.05%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LeonaBio, Inc. - Common Stock

News headline image
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
From LeonaBio, Inc.
Via GlobeNewswire
News headline image
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
From LeonaBio, Inc.
Via GlobeNewswire
News headline image
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
On Track to Complete Enrollment of the Phase 3 ELAINE-3 clinical trial in 4Q 2026 with Topline Data Expected in 2H 2027 
From LeonaBio, Inc.
Via GlobeNewswire
News headline image
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
Introduces brelgometon as the International Nonproprietary Name (INN) for ATH-1105 
From LeonaBio, Inc.
Via GlobeNewswire
LeonaBio (NASDAQ:LONA) Beats Q1 Loss Estimates as Phase 3 Breast Cancer Trial Enrollment Expands ↗
Via Chartmill
News headline image
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
From LeonaBio, Inc.
Via GlobeNewswire
News headline image
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
From LeonaBio, Inc.
Via GlobeNewswire
News headline image
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
Seasoned leaders bring deep experience in oncology and neurology drug development, corporate strategy, operational execution, and capital markets as company continues to advance clinical pipeline 
From LeonaBio, Inc.
Via GlobeNewswire
News headline image
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
From LeonaBio, Inc.
Via GlobeNewswire
News headline image
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data
Results showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancer 
From LeonaBio, Inc.
Via GlobeNewswire
News headline image
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
From LeonaBio, Inc.
Via GlobeNewswire
News headline image
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
Brings more than 25 years of biopharma business development and corporate strategy expertise 
From LeonaBio, Inc.
Via GlobeNewswire